Contineum Therapeutics (CTNM) Equity Ratio (2023 - 2026)
Contineum Therapeutics' Equity Ratio history spans 4 years, with the latest figure at 0.96 for Q1 2026.
- Quarterly Equity Ratio rose 2.66% to 0.96 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was 0.96 through Mar 2026, up 2.66% year-over-year, with the annual reading at 0.94 for FY2025, 1.38% up from the prior year.
- Equity Ratio came in at 0.96 for Q1 2026, up from 0.94 in the prior quarter.
- In the past five years, Equity Ratio ranged from a high of 0.98 in Q2 2024 to a low of 0.61 in Q1 2024.
- The 4-year median for Equity Ratio is 0.94 (2025), against an average of 0.65.
- Year-over-year, Equity Ratio skyrocketed 278.6% in 2024 and then fell 4.63% in 2025.
- Contineum Therapeutics' Equity Ratio stood at 0.52 in 2023, then surged by 278.6% to 0.93 in 2024, then increased by 1.38% to 0.94 in 2025, then increased by 1.41% to 0.96 in 2026.
- Per Business Quant, the three most recent readings for CTNM's Equity Ratio are 0.96 (Q1 2026), 0.94 (Q4 2025), and 0.95 (Q3 2025).